Periodic Reporting for period 3 - BEAMER (BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe)
Reporting period: 2023-09-01 to 2024-08-31
Adherence to treatment is crucial not only for optimizing patient benefits but also as a determinant for multiple health outcomes. It's noteworthy that roughly 25% of patients neglect preventive and disease management tasks like medication adherence, appointment maintenance, screenings, exercise, and dietary modifications. Alarmingly, close to half of all patients do not follow treatment suggestions, and in scenarios involving intricate treatment plans or substantial lifestyle adjustments, this non-compliance rate can soar to 70%.
Non-adherence to medication stands out as a significant impediment in efficiently handling chronic illnesses, resulting in deteriorated health, heightened hospitalizations, and a spike in mortality rates. Annually, non-adherence is implicated in approximately 125,000 premature deaths in the US and 200,000 in the EU. This not only leads to personal distress but also places a substantial financial strain on healthcare infrastructures.
Addressing this, the EU-backed BEAMER project is geared towards consolidating factors contributing to non-adherence to treatment, with an emphasis on behavioral aspects. We seek to develop a model to offer a robust understanding of the issue, ultimately enhancing the efficacy of forthcoming solutions. The model's objective is to pinpoint the key elements influencing adherence (structural and behavioural factors), facilitating the segmentation of populations according to their needs.
Cost consumption:
Travel cost: “general increase in travel cost post COVID, travels have been necessary to carry out our responsibilities”
Non -linear consumption of Direct person cost - relate to implementation of the action as UiO responsibility is considerable higher in from Y3 forward.
Can also announce that we will stay within Budget. Direct Personal Cost to support strictly necessary travels for carry out project work and dissemination in key strategic external events”
You may consider to allocate some of the salary budget to the travel budget, the activities at does not follow a linear distribution.
The activities will increase the last part of the project period (from year 3)
Non-adherence to medication stands out as a significant impediment in efficiently handling chronic illnesses, resulting in deteriorated health, heightened hospitalizations, and a spike in mortality rates. Annually, non-adherence is implicated in approximately 125,000 premature deaths in the US and 200,000 in the EU. This not only leads to personal distress but also places a substantial financial strain on healthcare infrastructures.
Addressing this, the EU-backed BEAMER project is geared towards consolidating factors contributing to non-adherence to treatment, with an emphasis on behavioral aspects. We seek to develop a model to offer a robust understanding of the issue, ultimately enhancing the efficacy of forthcoming solutions. The model's objective is to pinpoint the key elements influencing adherence (structural and behavioural factors), facilitating the segmentation of populations according to their needs.
Cost consumption:
Travel cost: “general increase in travel cost post COVID, travels have been necessary to carry out our responsibilities”
Non -linear consumption of Direct person cost - relate to implementation of the action as UiO responsibility is considerable higher in from Y3 forward.
Can also announce that we will stay within Budget. Direct Personal Cost to support strictly necessary travels for carry out project work and dissemination in key strategic external events”
You may consider to allocate some of the salary budget to the travel budget, the activities at does not follow a linear distribution.
The activities will increase the last part of the project period (from year 3)
During the recent phase, our project transitioned from conceptualization to modelling, primarily influenced by activities under WP2 and WP3. This model is bifurcated into: a core section rooted in behavioural factors, for which WP3 devised a dedicated questionnaire, and an external section influenced by WP1's previous findings. The consortium agreed that the model would yield two main outcomes: population segmentation and treatment adherence prediction. Concurrently, WP3 focused on drafting the BEAMER platform, discussing prerequisites with the technical team, and orchestrating pivotal tasks like data collection to support WP2 and the BEAMER questionnaire's finalization. This was complemented by an in-depth exploration of technological solutions, resulting in a preliminary BEAMER platform architecture, mock-ups, and defined user groups and workflows after extensive stakeholder engagement. While WP3's activities progressed, WP1 concentrated on the Data Lab's establishment. Although WP4's official commencement is pending, preliminary steps toward validation have begun. WP5 engaged in persona definition and scenario creation for BEAMER, which will be further refined in the project's third year alongside market analysis. With WP6's coordination shifting from UPORTO to UPM, there has been consistent oversight of the plan's seamless execution across all work packages. As year two concludes, the BEAMER model's functional design has been efficiently actualized, with forthcoming phases dedicated to rigorous testing, validation, and comprehensive stakeholder engagement.
The main output of this project will be a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through the improvement of the quality of life of individuals, enhancement of healthcare accessibility and sustainability. The model will allow for tailoring to individual's needs, using Real World Data captured from patients' behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey.
BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
The impact of the model implementation is hopefully the reform of the way healthcare is provided. By putting the patient at the core of its system, we aim to deliver high-value personalised care, increase the adherence of patients to therapy, and lead to a significant decrease in healthcare costs across Europe.
BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
The impact of the model implementation is hopefully the reform of the way healthcare is provided. By putting the patient at the core of its system, we aim to deliver high-value personalised care, increase the adherence of patients to therapy, and lead to a significant decrease in healthcare costs across Europe.